LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN AMPIO PHARMACEUTICALS, INC. AND DAEWOONG PHARMACEUTICALS CO., LTDLicense, Development and Commercialization Agreement • September 6th, 2018 • Aytu Bioscience, Inc • Pharmaceutical preparations • Delaware
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into on August 23, 2011 (the “Effective Date”) by and between Ampio Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111 (“Ampio”), and Daewoong Pharmaceuticals Co., Ltd, having its principal place of business at 163-3 Samsungdong, Kangnam-gu, Seoul, Republic of Korea (“Daewoong”). Each of Ampio and Daewoong is sometimes referred to herein as a “Party” and collectively, as the “Parties.”
VOTING AGREEMENTVoting Agreement • September 6th, 2018 • Aytu Bioscience, Inc • Pharmaceutical preparations • Delaware
THIS VOTING AGREEMENT (this “Agreement”), dated as of April 21, 2015, is made between Rosewind Corporation, a Colorado corporation (the “Company”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Shareholder”).
Amended and Restated Exclusive License AgreementExclusive License Agreement • September 6th, 2018 • Aytu Bioscience, Inc • Pharmaceutical preparations • Delaware
This Exclusive License Agreement (the “Agreement”) is entered into as of June 11, 2018 (the “Effective Date”) by and between Aytu BioScience, Inc., a Delaware corporation (“Licensee”), and Magna Pharmaceuticals, Inc. a Kentucky corporation (“Licensor”). Licensor and Licensee may be referred to herein individually as a “Party” or collectively, as the “Parties.”
